Cadila Healthcare Ahmedabad facility gets EIR from USFDA

The company's topical manufacturing facility at Ahmedabad has received an EIR from the United States Food and Drug Administration (USFDA) signifying the successful closure of the audit, Cadila Healthcare said in a filing to the BSE.

New Delhi: Drug firm Cadila Healthcare on Monday said it has received establishment inspection report (EIR) from the US health regulator after inspection of its Ahmedabad facility.

The company's topical manufacturing facility at Ahmedabad has received an EIR from the United States Food and Drug Administration (USFDA) signifying the successful closure of the audit, Cadila Healthcare said in a filing to the BSE.

Read also: Zydus Cadila gets DGCI nod for diabetes drug Saroglitazar Magnesium

The facility completed the USFDA audit from December 16 to 20, 2019 with zero 483 observations, it added.

Cadila was founded in 1952 by Ramanbhai Patel (1925–2001), formerly a lecturer in the L.M. College of Pharmacy, and his business partner Indravadan Modi. It evolved over the next four decades into an established pharmaceutical company.

Read also: Cadila Healthcare Ahmedabad facility clears USFDA inspection